The Institute of Cancer Research and Cancer Research Technology Make European BRCA2 Gene Patent Freely Available
11 August 2004
The Institute of Cancer Research and Cancer Research Technology Limited (CRT), the technology transfer company of the charity Cancer Research UK, today announced the availability of free licences of European patents on the hereditary breast cancer gene BRCA2 to publicly funded research laboratories and not-for-profit research laboratories.
The patents are based on the pioneering work of Professor Mike Stratton undertaken at The Institute of Cancer Research and funded by CRT's parent charity, Cancer Research UK.
Further instructions for obtaining the licence can be found in the Downloads section of CRT's website: www.cancertechnology.com/pages/about_download.html.
Notes To Editors
About The Institute of Cancer Research
The Institute of Cancer Research is a centre of excellence with leading scientists working on cutting edge research. It was founded in 1909 to carry out research into the causes of cancer and to develop new strategies for its prevention, diagnosis, treatment and care. Further information about The Institute of Cancer Research can be found at www.icr.ac.uk.
About Cancer Research Technology Limited
Cancer Research Technology Limited (CRT) is a specialist technology transfer company which aims to develop new discoveries in cancer research for the benefit of cancer patients. CRT is wholly owned by Cancer Research UK, the largest independent funder of cancer research in the world. CRT works closely with leading international cancer scientists and their institutes to protect intellectual property arising from their research and to establish links with commercial partners. CRT facilitates the discovery, development and marketing of new cancer therapeutics, vaccines, diagnostics and enabling technologies. Further information about CRT can be found at www.cancertechnology.com.
About Cancer Research UK
Cancer Research UK is Europe's leading cancer charity, dedicated to research into the causes, prevention and treatment of cancer. We support the work of 3,000 scientists, doctors and nurses in over 80 academic centres across the UK, with an annual scientific spend of more than £210 million. Cancer Research UK is the European leader in the development of novel anti-cancer treatments; from their discovery at the laboratory bench to early clinical trials in cancer patients. Further information about Cancer Research UK can be found at www.cancerresearchuk.org.
|
